Medgenics (MDGN) - NYSEMKT
  • Wed, Feb. 17, 9:54 AM
    • Medgenics (MDGN +5.8%) Q4 results: Revenues: $0; R&D Expense: $4.3M (+13.2%); SG&A: $2.1M (-12.5%); Net Loss: ($6.5M) (-4.8%); Loss Per Share: ($0.20) (+33.3%).
    • FY2015 results: Revenues: $0; R&D Expense: $15.4M (+85.5%); SG&A: $13M (+21.5%); Operating Loss: ($36.6M) (-93.7%); Net Loss: ($38M) (-106.5%); Loss Per Share: ($1.55) (-55.0%); Quick Assets: $33.3M (-37.3%).
    • No guidance given.
    | Wed, Feb. 17, 9:54 AM
  • Wed, Feb. 17, 8:04 AM
    | Wed, Feb. 17, 8:04 AM
  • Oct. 22, 2015, 10:34 AM
    • Medgenics (MDGN -0.3%) Q3 results: Revenues: $0; R&D Expense: $4.2M (+162.5%); SG&A: $3M (+30.4%); Operating Loss: ($15.4M) (-294.9%); Net Loss: ($16.5M) (-450.0%); Loss Per Share: ($0.66) (-214.3%); Quick Assets: $17.7M (-46.8%).
    • No guidance given.
    | Oct. 22, 2015, 10:34 AM
  • Oct. 22, 2015, 8:05 AM
    • Medgenics (NYSEMKT:MDGN): Q3 EPS of -$0.66
    | Oct. 22, 2015, 8:05 AM
  • Oct. 7, 2015, 6:57 PM
    • Medgenics (NYSEMKT:MDGN) commences a public of common stock. Price, volume and terms have yet to be announced.
    • Shares are unchanged in after hours trading.
    | Oct. 7, 2015, 6:57 PM
  • Oct. 1, 2015, 12:40 PM
    | Oct. 1, 2015, 12:40 PM | 1 Comment
  • Oct. 1, 2015, 9:00 AM
    • Medgenics (NYSEMKT:MDGN) is down 14% premarket on light volume in response to its announcement of a public offering of common stock. Price, volume and terms have yet to be announced.
    | Oct. 1, 2015, 9:00 AM
  • Aug. 10, 2015, 5:03 PM
    • Medgenics (NYSEMKT:MDGN): Q2 EPS of -$0.28 beats by $0.03.
    | Aug. 10, 2015, 5:03 PM
  • Jul. 15, 2015, 8:20 AM
    • Medgenics (NYSEMKT:MDGN) announces that the first patient has been enrolled in a Phase 2 clinical trial evaluating MDGN-201 (TARGTepo) for the treatment of anemia in patients with end stage renal disease undergoing peritoneal dialysis.
    • The primary endpoint of the 12-subject open label study is the maintenance of hemoglobin within the range of 9 - 12 g/dL for 52 weeks. The estimated completion date is September 2017.
    • MDGN-201's technology is called Transduced Autologous Restorative Gene Therapy ((TARGT)). According to the company, TARGT enables greater cell uptake, less immunogenicity, improved safety and tolerability and lower cost than other gene therapies.
    | Jul. 15, 2015, 8:20 AM
  • Jun. 24, 2015, 12:45 PM
    | Jun. 24, 2015, 12:45 PM | 3 Comments
  • Apr. 17, 2015, 8:14 AM
    • Medgenics (MDGN -2.1%) Q1 results: Revenues: $0; R&D Expense: $3.9M (+85.7%); SG&A: $3.9M (+25.8%); Operating Loss: ($7.9M) (-51.9%); Net Loss: ($8.9M) (-64.8%); Loss Per Share: ($0.36) (-28.6%); Quick Assets: $25.2M (-24.3%).
    • No guidance given.
    | Apr. 17, 2015, 8:14 AM
  • Apr. 17, 2015, 8:06 AM
    • Medgenics (NYSEMKT:MDGN): Q1 EPS of -$0.36 misses by $0.16.
    | Apr. 17, 2015, 8:06 AM | 2 Comments
  • Feb. 13, 2015, 8:29 AM
    • Medgenics (MDGN +0.1%) FY14 results: Revenues: $0; R&D Expense: $8.6M (+17.8%); SG&A: $10.7M (+1.9%); Operating Loss: ($18.9M) (-6.2%); Net Loss: ($18.4M) (-7.6%); Loss Per Share: ($1.00) (+5.7%); Quick Assets: $33.3M (+48.7%).
    • No guidance given.
    | Feb. 13, 2015, 8:29 AM
  • Feb. 13, 2015, 8:05 AM
    • Medgenics (NYSEMKT:MDGN): Q4 EPS of -$0.30.
    | Feb. 13, 2015, 8:05 AM
  • Dec. 9, 2014, 5:36 PM
    | Dec. 9, 2014, 5:36 PM
  • Dec. 8, 2014, 12:45 PM
    | Dec. 8, 2014, 12:45 PM | 4 Comments
Company Description
Medgenics, Inc. is a medical technology company, which develops protein therapeutics medical therapies. Its Transduced Autologous Restorative Gene Therapy platform is designed to provide sustained protein and peptide therapies to treat a range of chronic diseases and conditions. The Company was... More
Sector: Healthcare
Industry: Biotechnology
Country: United States